RT Journal Article
T1 Perinatal Derivatives: Where Do We Stand? A Roadmap of the Human Placenta and Consensus for Tissue and Cell Nomenclature.
A1 Silini, Antonietta Rosa
A1 Di Pietro, Roberta
A1 Lang-Olip, Ingrid
A1 Alviano, Francesco
A1 Banerjee, Asmita
A1 Basile, Mariangela
A1 Borutinskaite, Veronika
A1 Eissner, Günther
A1 Gellhaus, Alexandra
A1 Giebel, Bernd
A1 Huang, Yong-Can
A1 Janev, Aleksandar
A1 Kreft, Mateja Erdani
A1 Kupper, Nadja
A1 Abadía-Molina, Ana Clara
A1 Olivares, Enrique G
A1 Pandolfi, Assunta
A1 Papait, Andrea
A1 Pozzobon, Michela
A1 Ruiz-Ruiz, Carmen
A1 Soritau, Olga
A1 Susman, Sergiu
A1 Szukiewicz, Dariusz
A1 Weidinger, Adelheid
A1 Wolbank, Susanne
A1 Huppertz, Berthold
A1 Parolini, Ornella
K1 cells
K1 consensus nomenclature
K1 derivatives
K1 fetal annexes
K1 perinatal
K1 placenta
K1 tissues
AB Progress in the understanding of the biology of perinatal tissues has contributed to the breakthrough revelation of the therapeutic effects of perinatal derivatives (PnD), namely birth-associated tissues, cells, and secreted factors. The significant knowledge acquired in the past two decades, along with the increasing interest in perinatal derivatives, fuels an urgent need for the precise identification of PnD and the establishment of updated consensus criteria policies for their characterization. The aim of this review is not to go into detail on preclinical or clinical trials, but rather we address specific issues that are relevant for the definition/characterization of perinatal cells, starting from an understanding of the development of the human placenta, its structure, and the different cell populations that can be isolated from the different perinatal tissues. We describe where the cells are located within the placenta and their cell morphology and phenotype. We also propose nomenclature for the cell populations and derivatives discussed herein. This review is a joint effort from the COST SPRINT Action (CA17116), which broadly aims at approaching consensus for different aspects of PnD research, such as providing inputs for future standards for the processing and in vitro characterization and clinical application of PnD.
SN 2296-4185
YR 2020
FD 2020-12-17
LK http://hdl.handle.net/10668/16898
UL http://hdl.handle.net/10668/16898
LA en
DS RISalud
RD Apr 10, 2025